Erzofri is a drug owned by Luye Innomind Pharma (shijiazhuang) Co Ltd. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 24, 2039. Details of Erzofri's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11666573 | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
Sep, 2039
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Erzofri is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Erzofri's family patents as well as insights into ongoing legal events on those patents.
Erzofri's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Erzofri's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 24, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Erzofri Generic API suppliers:
Paliperidone Palmitate is the generic name for the brand Erzofri. 1 company has already filed for the generic of Erzofri. Check out the entire list of companies who have already received approval for Erzofri's generic
Alternative Brands for Erzofri
There are several other brand drugs using the same active ingredient (Paliperidone Palmitate) as Erzofri. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Janssen Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Paliperidone Palmitate, Erzofri's active ingredient. Check the complete list of approved generic manufacturers for Erzofri
About Erzofri
Erzofri is a drug owned by Luye Innomind Pharma (Shijiazhuang) Co Ltd. Erzofri uses Paliperidone Palmitate as an active ingredient. Erzofri was launched by Luye Innomind Pharma in 2024.
Approval Date:
Erzofri was approved by FDA for market use on 26 July, 2024.
Active Ingredient:
Erzofri uses Paliperidone Palmitate as the active ingredient. Check out other Drugs and Companies using Paliperidone Palmitate ingredient
Dosage:
Erzofri is available in suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 39MG/0.25ML (39MG/0.25ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 351MG/2.25ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 234MG/1.5ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 156MG/ML (156MG/ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 117MG/0.75ML (117MG/0.75ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 78MG/0.5ML (78MG/0.5ML) | SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |